RIPK1 and arthritic joint disease: In the case of chronic autoimmune collagen-induced arthritis, prophylactic treatment with the RIPK1 kinas inhibitor necrostatin-1s (Nec-1s) modestly reduced the incidence and severity of arthritis and was associated with reduced cytokine and necroptotic activity in the synovium, a skewing of the CD4+ T-cell response towards a TH2 and regulatory T-cell profile, and attenuated osteoclastogenesis [134].